GlassScriptPhysician profile
Anthony A Nuara
NPI 1912160482
$432,476.28
in general payments reported to CMS, 2019-2025
38 companies · $86K in 2025
The $86K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $22K · 2021: $26K · 2022: $39K · 2023: $86K · 2024: $109K · 2025: $86K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $209K · Consulting Fee: $25K · Honoraria: $18K · Food and Beverage: $17K · Travel and Lodging: $12K · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $209,127.00 |
| Consulting Fee | $24,885.00 |
| Honoraria | $18,400.00 |
| Food and Beverage | $16,796.32 |
| Travel and Lodging | $11,728.63 |
| Education | $139.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $106,261.79 | 2022-2024 | Vtama |
| Amgen INC. | $102,350.65 | 2019-2025 | Otezla, Otezla, Enbrel |
| E.R. Squibb & Sons, L.L.C. | $66,073.70 | 2021-2025 | Sotyktu |
| Celgene Corporation | $37,701.46 | 2019 | |
| Incyte Corporation | $35,639.61 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $33,849.39 | 2019-2025 | |
| Organon LLC | $21,467.23 | 2025 | Vtama, Hadlima |
| Galderma Laboratories, L.P. | $7,023.60 | 2019-2025 | Nemluvio |
| Janssen Biotech, INC. | $5,162.93 | 2019-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $4,472.96 | 2019-2025 | |
| Ucb, INC. | $2,735.11 | 2020-2025 | Bimzelx, Cimzia |
| Janssen Scientific Affairs, LLC | $2,028.87 | 2022 | |
| Arcutis Biotherapeutics, INC. | $1,643.83 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $1,148.56 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Lilly USA, LLC | $905.46 | 2019-2025 | Taltz, Olumiant, Ebglyss |
Show all 37 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Nuara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.